Pharmacodynamics of converting enzyme inhibition - PMC Back to Top Skip to main content
NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main …

1 Two single doses of 10 mg each of the converting enzyme inhibitor enalapril maleate or
MK‐421 and of its lysine analogue (MK‐521) were administered po to twelve male …

1 MK 421 and its lysine analogue are two new inhibitors of angiotensin converting enzyme.
Ten mg of both compounds were each given po to 12 normotensive volunteers to determine …

Nineteen hypertensive patients were treated with increasing doses of the new angiotensin-
converting enzyme inhibitor MK 421. Twenty milligrams orally reduced blood pressure from …

1 The disposition of two angiotensin converting‐enzyme inhibitor drugs was studied in
normal volunteers. One drug was enalapril maleate (MK‐421), which requires in vivo …

The antihypertensive, hemodynamic, and humoral effects of the new converting-enzyme
inhibitor enalapril (MK-421) were assessed by sequential studies during 3 months of …

This paper must necessarily take the form of a progress report. Many aspects of our work,
particularly with regard to human disposition and metabolism, are continuing at this time …

Since the end of 1976 ten orally active converting enzyme inhibitors [SQ 14,225 (captopril),
MK 421 (enalapril), MK 422, MK 521 (lysinopril), RHC 3659, CGS 13945, CGS 13928C …

The development of angiotensin converting enzyme inhibitors is often cited as a prime
example of task oriented research. The truth is far from this, and, as so often, chance played …

The effects of the new nonsulfhydryl-containing oral converting-enzyme inhibitor MK-521 on
blood pressure, heart rate, angiotensin-converting enzyme activity, plasma renin activity and …